Pharmaceuticals
credit of the month
Unattractive valuations and the overshadowing presence of patent pitfalls and litigation risk have combined to make the pharmaceutical sector one of the most interesting movers over the past few months.
Recently,Wyeth (WYE) was able to attract enough interest in a bond transaction to upsize the issue to $3 billion from $2.5 billion. Also, Schering-Plough (SPG) tapped the market for $2.4 billion in spite of ongoing legal issues and loss of patent protection on its Claritin product.
Just a month
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe
You are currently unable to print this content. Please contact [email protected] to find out more.
You are currently unable to copy this content. Please contact [email protected] to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
More on Structured products
Derivatives
CFTC’s Stump: new talks needed on offshore client clearing
Libor demise should spur rethink on US customer access to foreign clearing providers, says commissioner
Receive this by email